Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | NPY2R | P49146 | 6/20 | 0.46 |
| ▸ | NPY4R | P50391 | 6/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.46 |
| ▸ | NPY1R | P25929 | 4/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.45 |
| ▸ | CALCR | P30988 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31613776 | 0.96 | CALCRL (0.53) | CALCRLOPRM1OPRD1OPRK1CAPN1 | |
| SCHEMBL30432896 | 0.86 | CALCRL (0.51) | CALCRLNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL38659141 | 0.86 | CALCRL (0.45) | CALCRLOPRM1OPRD1OPRK1NPY2R | |
| SCHEMBL30166936 | 0.85 | NPY2R (0.50) | CALCRLNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30571129 | 0.84 | CAPN1 (0.52) | OPRM1OPRD1OPRK1CAPN1NPY2R | |
| SCHEMBL31500764 | 0.84 | CALCRL (0.48) | CALCRLOPRM1OPRK1 | |
| SCHEMBL30495754 | 0.84 | NPY2R (0.49) | CALCRLOPRM1OPRD1OPRK1NPY2R | |
| SCHEMBL31228800 | 0.84 | OPRM1 (0.48) | OPRM1OPRD1OPRK1CAPN1KEAP1 | |
| SCHEMBL30443912 | 0.84 | CALCRL (0.48) | CALCRLCAPN1KEAP1 | |
| SCHEMBL29461372 | 0.84 | OPRD1 (0.51) | OPRM1OPRD1OPRK1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4565281-A1 | SITE-SPECIFIC MODIFICATION BY A BBB-SHUTTLE OF ANTIBODY-BASED ENTITIES FOR CROSSING THE BLOOD-BRAIN BARRIER | Gate2Brain, S.L. (ES) | 2025-06-11 | — | — | EP | claimed |
| US-20260000784-A1 | PEPTIDIC WATER-SOLUBLE DELIVERY SYSTEM OF ANTICANCER DRUGS | HOSPITAL SANT JOAN DE DEU (ES) | 2026-01-01 | — | — | US | disclosed |
| EP-4565281-A1 | SITE-SPECIFIC MODIFICATION BY A BBB-SHUTTLE OF ANTIBODY-BASED ENTITIES FOR CROSSING THE BLOOD-BRAIN BARRIER | Gate2Brain, S.L. (ES) | 2025-06-11 | — | — | EP | disclosed |
| CN-119947759-A | Site-specific modification of BBB-shuttling agents through antibody-based entities for crossing the blood brain barrier | 盖特2布莱恩有限责任公司 | 2025-05-06 | — | — | CN | disclosed |
| EP-4499150-A1 | PEPTIDIC WATER-SOLUBLE DELIVERY SYSTEM OF ANTICANCER DRUGS | Hospital Sant Joan de Deu (ES) | 2025-02-05 | — | — | EP | disclosed |
| EP-4217007-B9 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2025-01-15 | — | — | EP | disclosed |
| EP-4217007-B1 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | FUNDACIO INST DE RECERCA BIOMEDICA IRB BARCELONA (ES) | 2024-11-06 | — | — | EP | disclosed |
| US-20240285784-A1 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | HOSPITAL SANT JOAN DE DEU (ES) | 2024-08-29 | — | — | US | disclosed |
| WO-2023186822-A1 | PEPTIDIC WATER-SOLUBLE DELIVERY SYSTEM OF ANTICANCER DRUGS | HOSPITAL SANT JOAN DE DEU (ES) | 2023-10-05 | — | — | WO | disclosed |
| EP-4217007-A1 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | Fundació Institut de Recerca Biomèdica (IRB Barcelona) (ES) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022064052-A1 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285784-A1 | PEPTIDIC CONJUGATES OF SN38 USEFUL IN THE TREATMENT OF CANCER | NGLY1, DNPEP, LNPEP | CALCRL 3809/4885OPRM1 2804/4885OPRD1 3995/4885 |
| US-20260000784-A1 | PEPTIDIC WATER-SOLUBLE DELIVERY SYSTEM OF ANTICANCER DRUGS | TP53, SGMS1, ABCB11 | CALCRL 661/4885OPRM1 2730/4885OPRD1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.